Company intelligence / Profile preview

SEED San Diego

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

SEED Therapeutics is a clinical-stage biotechnology company pioneering the discovery of molecular glues using its proprietary RITE3™ platform. The company harnesses the ubiquitin-proteasome system (UPS) to degrade harmful proteins that lack traditional druggable sites. The platform systematically selects from over 600 E3 ligases (both HECT and RING domain classes) rather than relying on just two well-known E3 ligases like competitors. The company has successfully applied its approach to nine active programs using six novel E3 ligases.

Therapeutic areas: OncologyNeurology
Modalities: Molecular glue therapy
Industry: Biotech

Beyond the preview

Go deeper on SEED San Diego.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEED San Diego.

Explore the full profile